[心力衰竭的向治疗:缺铁和静脉铁补充剂]
Josefine Rudolph1, Ryosuke Sato1,2, Stephan von Haehling1,2
1Klinik für Kardiologie und Pneumologie, Universitätsmedizin Göttingen, Göttingen.
Deutsche medizinische Wochenschrift (1946)
|March 9, 2026
概括
心力衰竭患者的铁缺乏症经常被忽视,但用静脉注射铁治疗可以改善症状并降低死亡率. 本综述涵盖了心力衰竭中缺铁的诊断和治疗策略.
科学领域:
- 心脏病学 心脏病学
- 血液学 血液学 血液学
- 内部医学 内部医学
背景情况:
- 铁缺乏症在心力衰竭患者中很常见.
- 铁缺乏症的诊断标准在心力衰竭中与一般人群相比有所不同.
- 在心力衰竭中,缺铁的低诊断和不充分的治疗是重要的问题.
研究的目的:
- 审查当前和新兴的铁缺乏心力衰竭的定义.
- 讨论这些定义对诊断的含义.
- 总结关于心力衰竭中缺铁的临床结果和治疗策略的证据.
主要方法:
- 关于心力衰竭中的铁缺乏研究的文献综述.
- 诊断标准及其影响的分析.
- 关于静脉注射铁治疗结果的证据综合.
主要成果:
- 静脉注射铁疗法可以改善心力衰竭症状,生活质量和运动能力.
- 静脉注射铁的治疗可以降低心力衰竭患者的发病率和死亡率.
- 当前的诊断方法可能会导致诊断不足.
结论:
- 准确的诊断和及时治疗铁缺乏症对于心力衰竭管理至关重要.
- 静脉注射铁是一种有效的治疗方法,可以改善心力衰竭的结果.
- 对最佳诊断标准和治疗策略的进一步研究是有必要的.
相关概念视频
Heart Failure VI: Adjunct Therapies
494
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
494
Heart Failure V: Medical Management
453
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
453
Heart Failure VII: Nursing Interventions
621
The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
621
Heart Failure IV: Classification and Diagnostic Evaluation
510
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
510
Heart Failure Drugs: Inotropic Agents
1.7K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.7K
Cardiomyopathy V: Interprofessional Care
566
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
566


